A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

References

• Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, et al. The trypanosomiases. Lancet. 2003;362:1469–80.
   PubMed Web of Science ®Google Scholar
• WHO. WHO/NTD Report update 2011. http://wwwwhoint/neglected_diseases/2010report/WHO_NTD_report_update_20 11pdf, 1–25. 2011.
   Google Scholar
• WHO. Neglected Tropical Diseases Booklet 2010. Neglected tropical diseases, hidden successes, emerging opportunities. 2010. http://whqlibdoc.who.int/publications/2009/9789241598705_eng.pdf, 1–71.
   Google Scholar
• Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, Ruiz JA, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr. 2010;9:57.
   PubMed Web of Science ®Google Scholar
• Simarro PP, Diarra A, Ruiz Postigo JA, Franco JR, Jannin JG . The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000–2009: the way forward. PLoS Negl Trop Dis. 2011;5:e1007.
   PubMed Web of Science ®Google Scholar
• WHO. African trypanosomiasis (sleeping sickness). 2012. http://wwwwhoint/mediacentre/factsheets/fs259/en/ (accessed 2012 April 4).
   Google Scholar
• Simarro PP, Franco JR, Cecchi G, Paone M, Diarra A, Ruiz Postigo JA, et al. Human African trypanosomiasis in non-endemic countries (2000–2010). J Travel Med. 2012;19:44–53.
   PubMed Web of Science ®Google Scholar
• Pepin J, Khonde N . Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Trans R Soc Trop Med Hyg. 1996;90:183–6.
   PubMed Web of Science ®Google Scholar
• Tong J, Valverde O, Mahoudeau C, Yun O, Chappuis F . Challenges of controlling sleeping sickness in areas of violent conflict: experience in the Democratic Republic of Congo. Confl Health. 2011;5:7.
   PubMedGoogle Scholar
• Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, McKerrow J, et al. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest. 2008;118:1301–10.
   PubMed Web of Science ®Google Scholar
• Baral TN . Immunobiology of African trypanosomes: need of alternative interventions. J Biomed Biotechnol. 2010;2010:389153.
   Google Scholar
• Stockdale C, Swiderski MR, Barry JD, McCulloch R . Antigenic variation in Trypanosoma brucei: joining the DOTs. PLoS Biol. 2008;6:e185.
   Google Scholar
• Brun R, Blum J, Chappuis F, Burri C . Human African trypanosomiasis. Lancet. 2010;375:148–59.
   PubMed Web of Science ®Google Scholar
• Matovu E, Seebeck T, Enyaru JC, Kaminsky R . Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 2001;3:763–70.
   PubMed Web of Science ®Google Scholar
• Barrett MP, Boykin DW, Brun R, Tidwell RR . Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol. 2007;152:1155–71.
   PubMed Web of Science ®Google Scholar
• Worthen C, Jensen BC, Parsons M . Diverse effects on mitochondrial and nuclear functions elicited by drugs and genetic knockdowns in bloodstream stage Trypanosoma brucei. PLoS Negl Trop Dis. 2010;4:e678.
   Google Scholar
• Steverding D . The development of drugs for treatment of sleeping sickness: a historical review. Parasit Vectors. 2010;3:15.
   PubMed Web of Science ®Google Scholar
• De Koning HP . Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol. 2001;59:586–92.
   PubMed Web of Science ®Google Scholar
• Wenzler T, Boykin DW, Ismail MA, Hall JE, Tidwell RR, Brun R . New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother. 2009;53:4185–92.
   PubMed Web of Science ®Google Scholar
• Sanderson L, Dogruel M, Rodgers J, De Koning HP, Thomas SA . Pentamidine movement across the murine blood–brain and blood–cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther. 2009;329:967–77.
   PubMed Web of Science ®Google Scholar
• Sanderson L, Khan A, Thomas S . Distribution of suramin, an antitrypanosomal drug, across the blood–brain and blood–cerebrospinal fluid interfaces in wild-type and P-glycoprotein transporter-deficient mice. Antimicrob Agents Chemother. 2007;51:3136–46.
   Web of Science ®Google Scholar
• Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, Checchi F . Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc Trop Med Hyg. 2009;103:280–90.
   PubMed Web of Science ®Google Scholar
• Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis. 2005;191:1922–31.
   PubMed Web of Science ®Google Scholar
• Kuepfer I, Schmid C, Allan M, Edielu A, Haary EP, Kakembo A, et al. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage Rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012;6:e1695.
   Google Scholar
• Rodgers J, Bradley B, Kennedy PG . Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitol Int. 2007;56:321–4.
   Web of Science ®Google Scholar
• Bouteille B, Oukem O, Bisser S, Dumas M . Treatment perspectives for human African trypanosomiasis. Fundam Clin Pharmacol. 2003;17:171–81.
   PubMed Web of Science ®Google Scholar
• Kennedy PG . Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest. 2004;113:496–504.
   PubMed Web of Science ®Google Scholar
• Barrett MP, Croft SL . Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104:175–96.
   PubMed Web of Science ®Google Scholar
• Kennedy PG . The pathogenesis and modulation of the post-treatment reactive encephalopathy in a mouse model of Human African Trypanosomiasis. J Neuroimmunol. 1999;100:36–41.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jennings FW, Kennedy PG, Murray M . The use of azathioprine to ameliorate post-treatment encephalopathy associated with African trypanosomiasis. Neuropathol Appl Neurobiol. 1992;18:619–25.
   Web of Science ®Google Scholar
• Baker N, de Koning HP, Maser P, Horn D . Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol. 2013;29:110–8.
   PubMed Web of Science ®Google Scholar
• Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, Grillet G, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ. 2008;336:705–8.
   PubMed Web of Science ®Google Scholar
• Simarro PP, Franco J, Diarra A, Postigo JA, Jannin J . Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis. Parasitology. 2012;139:842–6.
   PubMed Web of Science ®Google Scholar
• Sanderson L, Dogruel M, Rodgers J, Bradley B, Thomas SA . The blood–brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem. 2008;107:1136–46.
   PubMed Web of Science ®Google Scholar
• Kaiser M, Bray MA, Cal M, Bourdin Trunz B, Torreele E, Brun R . Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011;55:5602–8.
   PubMed Web of Science ®Google Scholar
• Hall BS, Bot C, Wilkinson SR . Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286:13088–95.
   PubMed Web of Science ®Google Scholar
• Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Miaka Mia Bilenge C, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. 2007;195:322–9.
   PubMed Web of Science ®Google Scholar
• Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, Checchi F, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials. 2006;1:e39.
   Google Scholar
• Chappuis F . Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go. Clin Infect Dis. 2007;45:1443–5.
   PubMed Web of Science ®Google Scholar
• Lutje V, Seixas J, Kennedy A . Chemotherapy for second-stage Human African trypanosomiasis. Cochrane Database Syst Rev. 2010;8:CD006201.
   Google Scholar
• Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, Priotto G . Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series. PLoS Negl Trop Dis. 2007;1:e64.
   Google Scholar
• Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. 2007;45:1435–42.
   PubMed Web of Science ®Google Scholar
• Yun O, Priotto G, Tong J, Flevaud L, Chappuis F . NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2010;4:e720.
   PubMed Web of Science ®Google Scholar
• Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, Mazue G, et al. Fexinidazole – a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4:e923.
   PubMed Web of Science ®Google Scholar
• Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E . Drug resistance in human African trypanosomiasis. Future Microbiol. 2011;6:1037–47.
   Web of Science ®Google Scholar
• Trunz BB, Jedrysiak R, Tweats D, Brun R, Kaiser M, Suwinski J, et al. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur J Med Chem. 2011;46:1524–35.
   PubMed Web of Science ®Google Scholar
• Nesslany F, Brugier S, Mouries MA, Le Curieux F, Marzin D . In vitro and in vivo chromosomal aberrations induced by megazol. Mutat Res. 2004;560:147–58.
   Web of Science ®Google Scholar
• Jacobs RT, Plattner JJ, Nare B, Wring SA, Chen D, Freund Y, et al. Benzoxaboroles: a new class of potential drugs for human African trypanosomiasis. Future Med Chem. 2011;3:1259–78.
   PubMed Web of Science ®Google Scholar
• DNDi. A needs-driven collaborative R&D model for neglected diseases. Geneva, Switzerland: R&D portfolio (Drugs for Neglected Diseases Initiative); 2011.
   Google Scholar
• DNDi. DNDi launches phase I in-human clinical trial for promising oral drug for sleeping sickness. Press Releases, 2012. http://wwwdndiorg/press-releases/press-releases-2012html (accessed 2012 March 29).
   Google Scholar
• Barrett MP . Potential new drugs for human African trypanosomiasis: some progress at last. Curr Opin Infect Dis. 2010;23:603–8.
   PubMed Web of Science ®Google Scholar
• Steverding D, Wang X . Evaluation of anti-sleeping-sickness drugs and topoisomerase inhibitors in combination on Trypanosoma brucei. J Antimicrob Chemother. 2009;63:1293–5.
   Web of Science ®Google Scholar
• Diaz-Gonzalez R, Perez-Pertejo Y, Prada CF, Fernandez-Rubio C, Balana-Fouce R, Reguera RM . Novel findings on trypanosomatid chemotherapy using DNA topoisomerase inhibitors. Mini Rev Med Chem. 2009;9:674–86.
   Web of Science ®Google Scholar
• Bakshi RP, Sang D, Morrell A, Cushman M, Shapiro TA . Activity of indenoisoquinolines against African trypanosomes. Antimicrob Agents Chemother. 2009;53:123–8.
   PubMed Web of Science ®Google Scholar
• Deterding A, Dungey FA, Thompson KA, Steverding D . Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Trop. 2005;93:311–6.
   PubMed Web of Science ®Google Scholar
• Rodgers J, Jones A, Gibaud S, Bradley B, McCabe C, Barrett MP, et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5:e1308.
   PubMed Web of Science ®Google Scholar
• Vodnala SK, Ferella M, Lunden-Miguel H, Betha E, van Reet N, Amin DN, et al. Preclinical assessment of the treatment of second-stage African trypanosomiasis with cordycepin and deoxycoformycin. PLoS Negl Trop Dis. 2009;3:e495.
   Google Scholar